Final Gcr Ppts Mba

7/31/2019 Final Gcr Ppts Mba

1/51

Click to edit Master subtitle style

5/29/12

AGlobal Country Report

onAustria

(Pharmaceutical sector)Presented by: Presented to:Stuti shah (2004) Gujarat TechnologicalSanat Thakur (2005) University

Dhruti ramanuj (2008)Meen dave (2009)Khushbu Vaghela (2010)Khushbu Soni (2025)


2/51

5/29/12

Present trade relation and

business volume betweenIndia and Austria


3/51

5/29/12

Indias Export fromAustria


4/51

5/29/12

Indias imports fromAustria


5/51

5/29/12

Introduction of PharmaceuticalSector

Austria consist of approximately 120

pharmaceutical companies

The Austrian Association of Pharmaceutical

Companies playsan important role

There are number of small and medium sized


6/51

5/29/12

50 % Small size enterprises with 9-10employees

40% Medium size enterprises with 10-250employees

10% of large size companies (responsiblefor 84% of the total industry turnover ) with

more than 250 employees.

Baxter is the biggest manufacturer


7/51

5/29/12

Other

marketleaders are


8/51

5/29/12

Demographic development and Medicalprogress are the causes of an increasingcost.

In age group of:

70-79 (23% of total costs)

60-69 (21% of total costs).

The costs per covered person are highest inage group 80+ with 902.


9/51

5/29/12

Functions of pharmaceutical sector

in Austria

In Austria there are approximately 330 hospitals.

Economic functions optimizing the purchaseand storage of drugs

Evaluating the cost-effectiveness of drugs


10/51

5/29/12

Focusing on quality management likeISO9000.

Providing best condition for optimum of

diagnostics, drug production and care fortherapy

Hauptverband (part of the umbrellaorganization of the Austrian Social Security)plays an important


11/51

5/29/12

Re-allocates hospital-based key accountmanagers (KAM) to communicate effectively.


12/51

5/29/12

Business activity of PharmaSector in Austria

Life sciences, pharmaceuticals andbiotechnology are the key areas

Austria offers well-established networks of,innovative biotechnology firms

Engaging pure research in the healthsector.


13/51

5/29/12

Focusing on red biotechnology, whitebiotechnology sector with products likeenzymes and food additive

It is specialize in Pharmaceutical agents,Diagnostics and New therapies

21% of companies of the Austrianbiotechnology industry work in R&D


14/51

5/29/12

Apeiron, Intercell AG, MarinomedBiotechnologie GmbH, Apomedica and

Apomeica are the various Austrianpharmaceutical firms are the firms engagedin different activities


15/51

5/29/12

Role of pharmaceutical industry in

the economy of AustriaRole as research innovators is positive

Expenditure on healthcare is higher

Patent provision in line with WTO/TRIPS

regulations.

Multinational co. production sites in Austria,


16/51

5/29/12

Role of pharmaceutical industry in

the economy of AustriaPharmaceutical innovations bring a therapeutic

progress in medicine.

Cardiovascular drugs leaders in market.

Latest pills and powders preference adds tocost.

Acts as inflator's.


17/51

5/29/12

Structure of pharmaceutical

Consumption.

Generic medicines.

Trends in consumption.

Production.


18/51

5/29/12

Structure of pharmaceutical

Trends in production.

Trade channels for market entry.

Price structure


19/51

5/29/12

Comparative position of

pharmaceutical industry with India

Pharmaceuticals are no more expensive.

Pharmaceutical companies leaders product andprocess innovations.

Pharmaceuticals 10 % cheaper than year 2000

Not affected by current financial crisis.


20/51

5/29/12

Present position and trend of

business with IndiaKey asset to the European economy as well as

Indian economy.

Indian pharmaceutical market is regulated by:

Drug Policy1986,

Pharmaceutical policy 2002,

National Pharmaceutical policy 2006.

The India's pharmaceutical market grew at 15.7


21/51

5/29/12

Present position and trend ofbusiness with India

Indian Prime Minister, Dr Manmohan Singh, hasdecided to continue with the 100 per cent foreigndirect investment (FDI) regime in the

pharmaceuticals sector.

In European country Austria was the 10th largestimporter of pharmaceutical products in 2008,accounting for 2.3% of total EU imports.


22/51

5/29/12

Present position and trend of

business with IndiaAustrias imports increased by an annual

average rate of 10% in value and 13% in volume,

amounting to 2.4 billion or 48 thousand tones in2008. Between 2004 and 2008.

Around 54% of Austrias exports was destined

for EU countries, and another 27% to non-EUcountries.


23/51

5/29/12

Policies and Norms of Austria forimport/export of pharmaceutical industry

Conclusions on the basis of Uruguay Roundnegotiations in context of pharmaceutical products:

Elimination of custom duty

Each government will fully implement the dutyelimination on the date of entry into force of theWorld Trade Organization (WTO) agreement, forthat government.


24/51

5/29/12

Policies and norms of India for

import and export to AustriaFormation of the EXIM policy.

Industrial licensing for all bulk drugs cleared byDrug Controller General (India), all theirintermediates and formulations will be abolished.

National pharmaceutical policy(NPP)


25/51

5/29/12


import and export to AustriaCustom Duty:

35% for standard areas

25% for preferential areas.

Introducing and Formulating Intellectual Property

protection Rights and TRIPS

Foreign direct investment is up to 100% will be

permitted


26/51

5/29/12


import and export to AustriaTwo major issues on account of

globalization and implementation of our

obligations under TRIPs:

The essentiality of improving incentives

for research and development in theIndian pharmaceutical industry

The need for reducing rigours of price


27/51


5/29/12

EU industry continues to encounter Some

Tariff and Non Tariff Barriers

In certain countries

such as India.


28/51

5/29/12

The key NTBs include:

A lack of transparency

Regulatory barriers

Intellectual property rights and the

counterfeiting of medicines


29/51

5/29/12

Potential for import/export in

Austria


30/51

5/29/12

Imports

European country Austria was the 10th

largest importer of pharmaceutical products in

2008.

It accounts for 2.3% of total EU imports

Imports from EU countries increased by an

annual average rate of 12% in terms of value

between 2004 and 2008.


31/51

5/29/12

Exports:

Austria was the 10th largest EU exporter, value

for 1.8% of total European pharmaceutical

exports.

Around 54% of Austrias exports was destined

for EU countries, and another 27% to non-EUcountries, excluding DCs. The country Russia,

the leading recipient from Austria, accounted for

18% of Austrian exports.


32/51

5/29/12

Opportunities and Threats:

+/- Although Austrias pharmaceutical imports wereincreased rapidly in the review period, they remainrelatively small. Exports are almost as big as the

imports

+ Austrias pharmaceutical imports from

developing countries are limited. Moreover, imports

from developing countries are dominated by India.

This countr will be a stron com etitor to other


33/51

5/29/12

+ Nonetheless, imports from developingcountries are increasing at fast rates, whichcould signify opportunities for developing country

exporters.


34/51


5/29/12

Business opportunities infuture


35/51

5/29/12

Business opportunities in IndianPharmacy IndustryIndia Business Strengths:

Extreme pharmaceutical market growth

potential, highly reliant on modernization and

reform.

Long-established trade patterns with Western

Europe and the US.


36/51

5/29/12

Strong local manufacturing sector with leading

domestic players establishing a notable

international presence.

Swift market approval times.

Low-cost but skilled English-speaking labor

force.


37/51

5/29/12

Business Opportunities:

Healthy generic and OTC drug market growth.

Increased public funding for disease eradication

programmers

Increasing demand for generic drugs in its Asian

neighbors, and globally.

Large and growing population boosting

pharmaceutical and medical demand.


38/51

5/29/12

Globally expansion of larger local companies.

Increasing research and development (R&D)

activity by domestic firms.

Underdeveloped market for chronic illnesses and

diagnostics.

The recognition of pharmaceutical patents from

January 2005.


39/51

5/29/12

Ongoing free trade agreement (FTA) negotiationswith the Association of South East Asian Nations

(ASEAN) group of countries and Austria.

Globally Increased demand for active

pharmaceutical ingredients (APIs) produced in

India.


40/51

5/29/12

Business Opportunities and threatsin Austria

+/-The consumption of pharmaceuticalproducts in Austria is increasing at significantrates, but the share of generic medicines in thetotal pharmaceutical market remains limited.

+ Due to Austrias cost-containment policiesinvolving the health-care sector, however, it is

possible that a rise in the consumption of

generic medicines will take place, which will

provide more opportunities for exporters of


41/51

5/29/12

+ Because of higher costs due to an ageing

population, Austria could provide opportunities fordeveloping countries. However, it is likely that alarge share of the products used are non-genericpharmaceuticals, which are of less importance to

developing country suppliers.


42/51

5/29/12

Conclusions

Tremendous growth of Indian market

Focusing on healthcare in western markets

Global ambitions to develop R&D

capabilities, to move in new drug

developments and to enter in the new

markets.


43/51

5/29/12

Conclusions

The sector got its momentum from government

policies which developed its inherent strength.

International drug-makers have introduced

generic or low-priced version of popular

medicines and have also decreased prices of

their existing products


44/51

5/29/12

The European has set out a number of tools

available to tackle relevant trade barriers and

resort to the Dispute Resolution settlement

mechanism.

The EUs pharmaceutical industry is a trade

success story and retains a strong position

with the global market.

Conclusions


45/51

5/29/12

Suggestions

The Indian pharmaceutical

market need to possess the

major opportunities for Indian

and multinational companies.


46/51

5/29/12

Suggestions

There should be proper focus on the investment

Strategy should be devised for the

pharmaceutical companies, to face competitive

pressure and maintain market standing.

Efforts should be made to develop retail sector.


47/51

5/29/12

Suggestions

The multinationals appear to have lost some

momentum and market share since 2000, so

action should be taken accordingly.

Large firm should be provided patented

products, as well as equal regulatory and

infrastructural support.


48/51

5/29/12

Suggestions

Indian pharmaceutical companies

should do well to recognize the

trends of global market and

prepare for its implications.


49/51

5/29/12

Strategies must be taken into account for

these implications.

Policy makers need to provide the

appropriate incentives to encourage access

and innovation.

The EU needs to trade carefully.


50/51

5/29/12

The

pharmaceutical


51/51

Thank You

Documents

Final Gcr Ppts Mba